Sudden cardiac death (SCD) in young competitive athletes is a rare but devastating event. The primary scope of pre-participation cardiovascular evaluation (PPE) is to identify silent cardiac diseases that may be associated with exercise-related sudden cardiac arrest or death.
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In 2016, the European Heart Rhythm Association (EHRA) and European Association of Preventive Cardiology (EAPC) branches of the European Society of Cardiology (ESC) published a consensus statement on PPE. The proposed protocol for PPE includes clinical history, physical examination, and a 12-lead resting electrocardiogram (ECG). The panel recommended to consider and advise for PPE in individuals performing regular, intense exercise, after proper information of both its benefits and limitations. 1 The evidence of favouring PPE comes from an observational study in the Vento region of Italy, where PPE for young competitive athletes is mandatory by Italian law since 1982. 2 The Italian PPE protocol differs from the European recommendation by including a constantload ECG stress test (EST).
Up to now, two large-scale studies have reported data on EST in PPE. Sofi and colleagues 3 evaluated an unselected population of 30,065 non-professional and professional athletes of a broad age range from 5 to 92 years (mean age 31 years), referred to obtain eligibility for competitive sports. EST showed an abnormal pattern in 4.9% of cases, with 0.2% being complex ventricular arrhythmia (VA). Overall, 0.6% of the total population was considered ineligible for competitive sports. No follow-up was performed. 3 Verdile and colleagues 4 screened 5283 professional athletes, selected for inclusion in national or Olympic teams (mean age 25 years), with the Italian protocol. 5.1% were excluded due to cardiovascular abnormalities. Of the remaining athletes, 0.7% exhibited complex VA and were temporarily disqualified from competitive sports. Two-thirds of the disqualified athletes experienced a reduction of VA over a period of 3 to 12 months and were allowed to resume competitive sports. Half of the remaining athletes consented to radiofrequency ablation, were successfully treated and competitive sports was permitted afterwards. No life-threatening arrhythmia occurred during a mean follow-up of 7.4 AE 5 years. 4 In this issue of the journal, Alessandro Zorzi and colleagues 5 added an interesting piece of evidence by studying EST in predominantly adolescent athletes with a prospective follow-up. The novelty in that study is an advanced imaging strategy, using cardiac magnetic resonance imaging (CMR) in athletes with complex VA. 5 The authors enrolled 10,985 consecutive non-professional athletes (median age 15 years) undergoing annual PPE. In the total cohort, 9% of the athletes had abnormal findings, 4% were detected with medical history, physical examination or resting ECG alone and another 5% only during EST. Importantly, 'abnormal' EST was defined as the occurrence of VA, most commonly premature ventricular beats, with couplets and non-sustained ventricular tachycardias in 14% of cases. No data are provided on ECG patterns suggestive of myocardial ischaemia, probably because of the young age of the population. Subsequent examinations in athletes with exercise-induced VA included 24-hour Holter monitoring and transthoracic echocardiography in all, and CMR in athletes with complex VA (17%). Genetic testing for catecholaminergic polymorphic ventricular tachycardia was performed in 1% of the athletes. Overall, 0.49% of athletes showed a cardiac pathology at risk of SCD and were disqualified from competitive sports, a number comparable with the study of Sofi et al., 3 despite the different study design and age ranges. Compared to routine PPE, the addition of EST increased the diagnostic yield by 75%. Twothirds of the cardiac diseases at risk detected by EST were due to two diagnoses, namely idiopathic nonischaemic scar (43%) and arrhythmogenic right ventricular cardiomyopathy (ARVC, 22%). EST resulted in an additional 470 false positive cases, reducing the positive predictive value of PPE from 6.9% to 5.5% (-20%). During a mean follow-up of 32 AE 21 months, no cardiac event occurred in either healthy or diseased athletes.
Three aspects of the paper need special attention. (a) The aim of the study was to evaluate whether exerciseinduced VA has the potential to guide subsequent diagnostic strategy and to detect subclinical cardiac disease at risk of SCD better than history, physical examination and resting ECG alone. In this context, the constant load EST of the Italian protocol may be viewed as a limitation. In their cohort, peak heart rate at the end of the EST reached 90% of the predicted heart rate. A recent scientific statement of the American Heart Association and American College of Cardiology recommended that the exercise testing protocol should be based on maximal performance rather than achieving 80-100% of the target heart rate to reach as closely as possible the level of exertion achieved during competitive sport. 6 Thus, the diagnostic yield of a true maximal EST may have been higher.
(b) The validity and reproducibility of EST have not been adequately studied in an athletic population, questioning the clinical applicability. This may be illustrated by reviewing the discrepant findings of EST and 24-hour ECG monitoring including a training session. Only 38% of athletes with VA during EST had VA during 24-hour ambulatory ECG monitoring, despite comparable peak heart rates of 90% or greater of predicted. The presence of left ventricular (LV) late gadolinium enhancement was associated with complex VA during EST, but not during 24-hour ambulatory ECG monitoring. In contrast, the premature ventricular beats count was significantly higher among athletes with no LV late gadolinium enhancement.
(c) Mainly two pathologies, namely ARVC and nonischaemic LV scar, were responsible for the incremental diagnostic yield of EST. Fifty-six per cent of cases of ARVC were detected only during EST, which is unusual and possibly related to the early stage phenotype in adolescents. As the study was conducted in the Veneto region of Italy, the prevalence of ARVC was probably high. 7 Thus, the diagnostic yield of EST could be lower in older athletes (in whom ARVC is already detected in the resting ECG) and in regions with a lower prevalence of ARVC. Despite the fact that non-ischaemic LV scar has been identified as a substrate for life-threatening VA, 8 and has been the most frequent finding in an autopsy study on SCD during sports, 9 the overall prognosis and best therapeutic strategy currently remains unknown and is a matter of debate. Heterogeneous athletic populations, small sample sizes, short-term followup and the fact that the majority of athletes with non-ischaemic LV scar have an uneventful course complicate evidence-based clinical decision-making. For example, in the current study, 0% of athletes with non-ischaemic LV scar experienced malignant arrhythmia during follow-up, compared to 22% in a slightly older athletic population (mean age 33 years) with a comparable follow-up of 38 AE 25 months. 8 In the United Kingdom regional registry, 26% of deceased athletes with non-ischaemic LV scar had died at rest, highlighting other potential triggers than exercise for life-threatening VA. 10 What are the clinical implications of the study by Zorzi et al? 5 The answer may be different from an Italian and European perspective. Within the framework of the distinct Italian sports law, criteria have been established to disqualify athletes at risk from competitive sports. One criterion for disqualification is complex VA in the presence of non-ischaemic LV scar, following a current position statement of the sport cardiology section of the EAPC on cardiomyopathies, myocarditis and pericarditis. 11 With this approach, the incremental diagnostic yield of EST may be viewed as an additional value. However, this aspect has to be weighted against the overall very low number of athletes at risk, and the substantial increase in false positive tests, resulting in additional costs for downstream testing. The latter points support the current European position paper that does not include EST in PPE. 1 Most importantly, the data of Zorzi and colleagues 5 add to the evidence that cardiac diseases at risk of SCD are rare in young athletes, even if sophisticated screening tools such as CMR are used. This is reassuring for athletes, their families and trainers. Some athletes may have an indication to sweat during an EST, but most of them can safely sweat during competitions.
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